Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822249 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1 | |
| SCHEMBL1827072 | 0.91 | KCNA5 (0.38) | F10F2PRSS1L3MBTL1 | |
| SCHEMBL1823820 | 0.89 | ALDH1A1 (0.34) | F10F2PRSS1ALDH1A1L3MBTL1 | |
| SCHEMBL1822400 | 0.88 | HSD11B1 (0.37) | F10F2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3572878 | 0.88 | KMT2A (0.41) | — | |
| SCHEMBL1826337 | 0.88 | GAA (0.37) | ALDH1A1MAPTL3MBTL1HPGDCYP2D6 | |
| SCHEMBL1826942 | 0.87 | STS (0.39) | F10F2ALDH1A1HPGDGAA | |
| SCHEMBL1823956 | 0.85 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1HPGD | |
| SCHEMBL3578426 | 0.84 | KMT2A (0.43) | F10F2PRSS1CYP2D6SLC6A2 | |
| SCHEMBL1828934 | 0.82 | KMT2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161254-B1 | Intermediate for preparing a biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-1481967-B1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-2161254-A1 | Intermediate for preparing a biaryl compound | Sumitomo Chemical Company, Limited (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1481967-A1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | F10 1460/4885F2 701/4885PRSS1 4551/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | F10 1977/4885F2 805/4885PRSS1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.